Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2007

01-06-2007 | Populations at Risk

The Demise of Oregon’s Medically Needy Program: Effects of Losing Prescription Drug Coverage

Authors: Judy Zerzan, MD, MPH, Tina Edlund, MS, Lisa Krois, MPH, Jeanene Smith, MD, MPH

Published in: Journal of General Internal Medicine | Issue 6/2007

Login to get access

Abstract

BACKGROUND

In January 2003, people covered by Oregon’s Medically Needy program lost benefits owing to state budget shortfalls. The Medically Needy program is a federally matched optional Medicaid program. In Oregon, this program mainly provided prescription drug benefits.

OBJECTIVE

To describe the Medically Needy population and determine how benefit loss affected this population’s health and prescription use.

DESIGN

A 49-question telephone survey instrument created by the research team and administered by a research contractor.

PARTICIPANTS

A random sample of 1,269 eligible enrollees in Oregon’s Medically Needy Program. Response rate was 35% with 439 individuals, ages 21–91 and 64% women, completing the survey.

MEASUREMENTS

Demographics, health information, and medicatication use at the time of the survey obtained from the interview. Medication use during the program obtained from administrative data.

RESULTS

In the 6 months after the Medically Needy program ended, 75% had skipped or stopped medications. Sixty percent of the respondents had cut back on their food budget, 47% had borrowed money, and 49% had skipped paying other bills to pay for medications. By self-report, there was no significant difference in emergency department visits, but a significant decrease in hospitalizations comparing 6 months before and after losing the program. Two-thirds of respondents rated their current health as poor or fair.

CONCLUSIONS

The Medically Needy program provided coverage for a low-income, chronically ill population. Since its termination, enrollees have decreased prescription drug use and increased financial burden. As states make program changes and Medicare Part D evolves, effects on vulnerable populations must be considered.
Literature
1.
go back to reference Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees—a call to action. N Engl J Med. 1999;340:722–8.PubMedCrossRef Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees—a call to action. N Engl J Med. 1999;340:722–8.PubMedCrossRef
2.
go back to reference Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Project Hope). 1999;18:201–12.CrossRef Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Project Hope). 1999;18:201–12.CrossRef
3.
go back to reference Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384–91.PubMedCrossRef Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384–91.PubMedCrossRef
4.
go back to reference Safran DG. Seniors and prescription drugs: findings from a 2001 survey of seniors in eight states. The Commonwealth Fund/Kaiser Family Foundation/Tufts-New England Medical Center; July 2002. Safran DG. Seniors and prescription drugs: findings from a 2001 survey of seniors in eight states. The Commonwealth Fund/Kaiser Family Foundation/Tufts-New England Medical Center; July 2002.
5.
go back to reference Xu KT. Financial disparities in prescription drug use between elderly and nonelderly Americans. Health Aff (Project Hope). 2003;22:210–21.CrossRef Xu KT. Financial disparities in prescription drug use between elderly and nonelderly Americans. Health Aff (Project Hope). 2003;22:210–21.CrossRef
6.
go back to reference Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM. Effect of generic-only drug benefits on seniors’ medication use and financial burden. Am J Manag Care. 2006;12:525–32.PubMed Tseng CW, Brook RH, Keeler E, Steers WN, Waitzfelder BE, Mangione CM. Effect of generic-only drug benefits on seniors’ medication use and financial burden. Am J Manag Care. 2006;12:525–32.PubMed
7.
go back to reference Lurie N, Ward NB, Shapiro MF, Brook RH. Termination from Medi-Cal—does it affect health? N Engl J Med. 1984;311:480–4.PubMedCrossRef Lurie N, Ward NB, Shapiro MF, Brook RH. Termination from Medi-Cal—does it affect health? N Engl J Med. 1984;311:480–4.PubMedCrossRef
8.
go back to reference Lurie N, Ward NB, Shapiro MF, Gallego C, Vaghaiwalla R, Brook RH. Termination of Medi-Cal benefits. A follow-up study one year later. N Engl J Med. 1986;314:1266–8.PubMedCrossRef Lurie N, Ward NB, Shapiro MF, Gallego C, Vaghaiwalla R, Brook RH. Termination of Medi-Cal benefits. A follow-up study one year later. N Engl J Med. 1986;314:1266–8.PubMedCrossRef
9.
go back to reference Saver BG, Doescher MP, Jackson JE, Fishman P. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health. 2004;7:133–43.PubMedCrossRef Saver BG, Doescher MP, Jackson JE, Fishman P. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health. 2004;7:133–43.PubMedCrossRef
10.
go back to reference Kleinke JD. The price of progress: prescription drugs in the health care market. Health Aff (Project Hope). 2001;20:43–60.CrossRef Kleinke JD. The price of progress: prescription drugs in the health care market. Health Aff (Project Hope). 2001;20:43–60.CrossRef
11.
go back to reference Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA. 2003;290:222–7.PubMedCrossRef Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA. 2003;290:222–7.PubMedCrossRef
12.
go back to reference Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28:907–17.PubMedCrossRef Harris BL, Stergachis A, Ried LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28:907–17.PubMedCrossRef
13.
go back to reference Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35:1119–31.PubMedCrossRef Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35:1119–31.PubMedCrossRef
15.
go back to reference Oregon Department of Human Services Memo. Oregon Department of Human Services, State of Oregon; June 2003. Oregon Department of Human Services Memo. Oregon Department of Human Services, State of Oregon; June 2003.
17.
go back to reference Brodie M, Blendon R. National survey on prescription drugs. Health Desk: A Partnership of the Kaiser Family Foundation and the Newshour with Jim Lehrer; 2000. Brodie M, Blendon R. National survey on prescription drugs. Health Desk: A Partnership of the Kaiser Family Foundation and the Newshour with Jim Lehrer; 2000.
18.
go back to reference Berk ML, Schur CL, Mohr P. Using survey data to estimate prescription drug costs. Health Aff (Project Hope). 1990;9:146–56.CrossRef Berk ML, Schur CL, Mohr P. Using survey data to estimate prescription drug costs. Health Aff (Project Hope). 1990;9:146–56.CrossRef
19.
go back to reference Barnes PM, Adams PF, Schiller JS. Summary of health statistics for the US population: National Health Interview Survey, 2001. National Center for Health Statistics. Vital Health Stat. 2003;27. Barnes PM, Adams PF, Schiller JS. Summary of health statistics for the US population: National Health Interview Survey, 2001. National Center for Health Statistics. Vital Health Stat. 2003;27.
20.
go back to reference CDC Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. 2004. Available at: http://www.cdc.gov/brfss/. Accessed October 18, 2006. CDC Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. 2004. Available at: http://​www.​cdc.​gov/​brfss/​. Accessed October 18, 2006.
22.
go back to reference Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff (Project Hope). 2005;24:780–9.CrossRef Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff (Project Hope). 2005;24:780–9.CrossRef
23.
go back to reference Piette JD, Heisler M. Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care. 2004;10:861–8.PubMed Piette JD, Heisler M. Problems due to medication costs among VA and non-VA patients with chronic illnesses. Am J Manag Care. 2004;10:861–8.PubMed
24.
go back to reference Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Pub Health. 2004;94:1782–7.PubMedCrossRef Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Pub Health. 2004;94:1782–7.PubMedCrossRef
25.
go back to reference Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952–60.PubMedCrossRef Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292:952–60.PubMedCrossRef
26.
go back to reference Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550–6.PubMedCrossRef Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550–6.PubMedCrossRef
27.
go back to reference Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072–7.PubMedCrossRef Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin T, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072–7.PubMedCrossRef
28.
go back to reference Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293–304.PubMedCrossRef Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293–304.PubMedCrossRef
29.
go back to reference Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–9.PubMedCrossRef Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421–9.PubMedCrossRef
30.
go back to reference Rector TS, Venus PJ. Do drug benefits help Medicare beneficiaries afford prescribed drugs? Health Aff (Project Hope). 2004;23:213.CrossRef Rector TS, Venus PJ. Do drug benefits help Medicare beneficiaries afford prescribed drugs? Health Aff (Project Hope). 2004;23:213.CrossRef
31.
go back to reference Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Project Hope). 2003;22:220–9.CrossRef Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Project Hope). 2003;22:220–9.CrossRef
32.
go back to reference Caskie GI, Willis SL. Congruence of self-reported medications with pharmacy prescription records in low-income older adults. Gerontologist. 2004;44:176–85.PubMed Caskie GI, Willis SL. Congruence of self-reported medications with pharmacy prescription records in low-income older adults. Gerontologist. 2004;44:176–85.PubMed
33.
go back to reference Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159:308–17.PubMedCrossRef Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol. 2004;159:308–17.PubMedCrossRef
34.
go back to reference Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA. Reliability of Group Health Cooperative automated pharmacy data by drug benefit status. Pharmacoepidemiol Drug Saf. 2005;14:877–84.PubMedCrossRef Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA. Reliability of Group Health Cooperative automated pharmacy data by drug benefit status. Pharmacoepidemiol Drug Saf. 2005;14:877–84.PubMedCrossRef
36.
go back to reference Baugh DK, Pine PL, Blackwell S, Ciborowski G. Medicaid prescription drug spending in the 1990s: a decade of change. Health Care Financ Rev. 2004;25:5–23.PubMed Baugh DK, Pine PL, Blackwell S, Ciborowski G. Medicaid prescription drug spending in the 1990s: a decade of change. Health Care Financ Rev. 2004;25:5–23.PubMed
Metadata
Title
The Demise of Oregon’s Medically Needy Program: Effects of Losing Prescription Drug Coverage
Authors
Judy Zerzan, MD, MPH
Tina Edlund, MS
Lisa Krois, MPH
Jeanene Smith, MD, MPH
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2007
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-007-0178-4

Other articles of this Issue 6/2007

Journal of General Internal Medicine 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine